Combination of Lenalidomide and Obinutuzumab (GA101) in Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Phase of Trial: Phase II
Latest Information Update: 01 Feb 2017
At a glance
- Drugs Lenalidomide (Primary) ; Obinutuzumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 31 Mar 2016 According to ClinicalTrials.gov record,time frame for primary end point has been changed from 9-12 months to 3 months.
- 31 Mar 2016 Planned primary completion date changed from 1 Oct 2023 to 1 Mar 2023 as reported by ClinicalTrials.gov record.
- 31 Mar 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.